Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Delfi Diagnostics is raising $101,074,986.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Victor Velculescu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Delfi Diagnostics

DELFI Diagnostics is a Baltimore-based startup focused on the non-invasive detection of cancer at earlier stages, when it is most curable. DELFI uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer. These analyses are performed through simultaneous examination of millions of DNA sequences using machine learning to identify tumor-specific abnormalities.

To learn more about Delfi Diagnostics, visit http://delfidiagnostics.com/

Contact:
Victor Velculescu, Chief Executive Officer
410-696-3304
https://www.linkedin.com/in/victor-velculescu-md-phd-1241716/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved